46-60 of 188
Navigating Treatment Goals in IgAN: The Impact of ET-1 and Ang II
Clinician's RoundtableNavigating Treatment Goals in IgAN: The Impact of ET-1 and Ang II
Charles Turck, PharmD, BCPS, BCCCP
Jonathan Barratt, MD, PhD
Shikha Wadhwani, MD
Deciphering the Link: Proteinuria and eGFR Dynamics in IgAN and FSGS
Clinician's RoundtableDeciphering the Link: Proteinuria and eGFR Dynamics in IgAN and FSGS
Gates B. Colbert, MD
Jonathan Barratt, MD, PhD
Proteinuria in CKD Progression: Understanding Its Role and Monitoring Strategies
Clinician's RoundtableProteinuria in CKD Progression: Understanding Its Role and Monitoring Strategies
Gates B. Colbert, MD
Jared Hassler, MD
Innovations in IgAN Care: Addressing Challenges with Therapeutic Advances
Clinician's RoundtableInnovations in IgAN Care: Addressing Challenges with Therapeutic Advances
Charles Turck, PharmD, BCPS, BCCCP
Pietro A. Canetta, MD
Moving Beyond Immunosuppressive Therapy in IgAN
Clinician's RoundtableMoving Beyond Immunosuppressive Therapy in IgAN
Gates B. Colbert, MD
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Project Oncology®From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
- advertisement
Difelikefalin: Managing CKD-aP for Improved Quality of Life
NephrologyDifelikefalin: Managing CKD-aP for Improved Quality of Life
Jörg Latus, MD
IgA Nephropathy Updates: Evolving Guidelines and Practical Strategies
NephrologyIgA Nephropathy Updates: Evolving Guidelines and Practical Strategies
Jörg Latus, MD
Jürgen Floege, MD
Identifying C3G: Key Diagnostic Considerations and Challenges
On the Frontlines of C3GIdentifying C3G: Key Diagnostic Considerations and Challenges
Anuja Java, MD
Transforming C3G Care: New Advances in Targeted Treatment
On the Frontlines of C3GTransforming C3G Care: New Advances in Targeted Treatment
Anuja Java, MD
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Project Oncology®Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Ryan Quigley
David F. McDermott, MD
Osteoporosis in CKD: Closing the Gaps in Diagnosis and Treatment
On the Frontlines of OsteoporosisOsteoporosis in CKD: Closing the Gaps in Diagnosis and Treatment
Ryan Quigley
Charles Ginsberg, MD
- advertisement
Topline Results of the CONFIDENCE Trial
DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF)Topline Results of the CONFIDENCE Trial
Rajiv Agarwal, MBBS, MD, FASN, BRCU
The CONFIDENCE Trial: Data Insights
DataPulse: Key Clinical Trial Insights on Nonsteroidal MRAs in CKM Syndrome ManagementThe CONFIDENCE Trial: Data Insights
prof. Hiddo Heerspink
Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF)Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
Finnian R. McCausland, MD
